Yale Mitchel

5.9k total citations · 2 hit papers
71 papers, 3.4k citations indexed

About

Yale Mitchel is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Yale Mitchel has authored 71 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Surgery, 36 papers in Endocrinology, Diabetes and Metabolism and 15 papers in Economics and Econometrics. Recurrent topics in Yale Mitchel's work include Lipoproteins and Cardiovascular Health (59 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (28 papers) and Cancer, Lipids, and Metabolism (15 papers). Yale Mitchel is often cited by papers focused on Lipoproteins and Cardiovascular Health (59 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (28 papers) and Cancer, Lipids, and Metabolism (15 papers). Yale Mitchel collaborates with scholars based in United States, Norway and Australia. Yale Mitchel's co-authors include Sukrut Shah, Michael H. Davidson, Hayes M. Dansky, Aditi Sapre, Christopher P. Cannon, Harold Bays, Eliot A. Brinton, Antonio M. Gotto, Philip J. Barter and Michael Stepanavage and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Yale Mitchel

69 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

2010 544 citations Christopher P. Cannon, Sukrut Shah et al. profile →
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616

2023 109 citations Christie M. Ballantyne, Puja Banka et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yale Mitchel United States	32	2.7k	1.6k	795	708	624	71	3.4k
James H. Revkin United States	18	3.2k 1.2×	2.3k 1.4×	879 1.1×	1.2k 1.7×	485 0.8×	39	4.8k
Matthew K. Ito United States	24	2.8k 1.0×	1.2k 0.7×	600 0.8×	858 1.2×	912 1.5×	71	3.9k
Valerie A. Cain United States	19	3.0k 1.1×	1.6k 1.0×	579 0.7×	1.0k 1.4×	792 1.3×	33	4.2k
Claude Gagné Canada	34	2.6k 1.0×	1.9k 1.2×	858 1.1×	1.1k 1.6×	408 0.7×	77	4.0k
William B. Kruyer United States	7	3.4k 1.3×	1.5k 1.0×	752 0.9×	1.2k 1.6×	1.2k 1.9×	17	4.4k
Leiv Ose Norway	43	3.6k 1.3×	1.6k 1.0×	1.0k 1.3×	910 1.3×	614 1.0×	161	5.8k
David A. DeMicco United States	33	2.6k 1.0×	1.8k 1.1×	534 0.7×	1.5k 2.1×	600 1.0×	69	4.5k
C Pollicino Australia	6	3.5k 1.3×	1.6k 1.0×	852 1.1×	1.3k 1.9×	1.3k 2.1×	9	5.1k
Leslie Lipka United States	24	2.4k 0.9×	762 0.5×	902 1.1×	1.0k 1.5×	708 1.1×	44	3.7k
Pedro Mata Spain	36	2.7k 1.0×	1.0k 0.6×	934 1.2×	830 1.2×	517 0.8×	119	4.0k

Countries citing papers authored by Yale Mitchel

Since Specialization

Citations

This map shows the geographic impact of Yale Mitchel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yale Mitchel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yale Mitchel more than expected).

Fields of papers citing papers by Yale Mitchel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yale Mitchel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yale Mitchel. The network helps show where Yale Mitchel may publish in the future.

Co-authorship network of co-authors of Yale Mitchel

This figure shows the co-authorship network connecting the top 25 collaborators of Yale Mitchel. A scholar is included among the top collaborators of Yale Mitchel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yale Mitchel. Yale Mitchel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ballantyne, Christie M., Puja Banka, Gustavo Méndez, et al.. (2023). Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. Journal of the American College of Cardiology. 81(16). 1553–1564. 109 indexed citations breakdown →

Ballantyne, Christie M., Sukrut Shah, Aditi Sapre, et al.. (2017). A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 120(4). 569–576. 9 indexed citations

Bohula, Erin A., David A. Morrow, Robert P. Giugliano, et al.. (2017). Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology. 69(8). 911–921. 117 indexed citations

Ballantyne, Christie M., Sukrut Shah, Uma Kher, et al.. (2016). Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 119(3). 388–396. 12 indexed citations

Brinton, Eliot A., Joseph Triscari, Philippe Brudi, et al.. (2016). Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in Health and Disease. 15(1). 116–116. 3 indexed citations

Kastelein, John J.P., Joost Besseling, Sukrut Shah, et al.. (2015). Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. 385(9983). 2153–2161. 80 indexed citations

Gotto, Antonio M., Christopher P. Cannon, Sukrut Shah, et al.. (2011). Abstract 15035: Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. Circulation. 124(10). 3673–81. 4 indexed citations

Dansky, Hayes M., Daniel M. Bloomfield, Patrice H. Gibbons, et al.. (2011). Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. American Heart Journal. 162(4). 708–716. 24 indexed citations

Gutstein, David E., Rajesh Krishna, Douglas G. Johns, et al.. (2011). Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction. Clinical Pharmacology & Therapeutics. 91(1). 109–122. 47 indexed citations

10.

McKenney, James M., Harold Bays, Michael J. Koren, et al.. (2010). Safety of extended-release niacin/laropiprant in patients with dyslipidemia. Journal of clinical lipidology. 4(2). 105–112.e1. 27 indexed citations

11.

Paolini, John F., Yale Mitchel, Rafael Reyes, et al.. (2008). Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial. International Journal of Clinical Practice. 62(6). 896–904. 14 indexed citations

12.

Farnier, Michel, et al.. (2008). VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. Journal of Lipid Research. 49(12). 2641–2647. 14 indexed citations

13.

Feldman, Theodore, Leiv Ose, Arvind Shah, et al.. (2007). Efficacy and Safety of Ezetimibe/Simvastatin Versus Simvastatin Monotherapy in Hypercholesterolemic Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 5(1). 13–21. 6 indexed citations

14.

Paolini, John F., Yale Mitchel, Robert Reyes, et al.. (2007). Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.. The American Journal of Cardiology. 101(5). 625–630. 128 indexed citations

15.

McKenney, James M., Michel Farnier, Harold Bays, et al.. (2006). Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia. Journal of the American College of Cardiology. 47(8). 1584–1587. 90 indexed citations

16.

Ose, Leiv, Arvind Shah, Michael J. Davies, et al.. (2006). Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Current Medical Research and Opinion. 22(5). 823–835. 17 indexed citations

17.

Lewin, Andrew, Mark Kipnes, Luigi Meneghini, et al.. (2004). Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 26(3). 379–389. 31 indexed citations

18.

Goldberg, Anne C., Rachel Capece, Aditi Sapre, Ji Liu, & Yale Mitchel. (2004). 1084-174 Efficacy of ezetimibe-10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia. Journal of the American College of Cardiology. 43(5). A480–A480. 3 indexed citations

19.

Dobs, Adrian S., Helmut G. Schrott, Michael H. Davidson, et al.. (2000). Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 49(9). 1234–1238. 82 indexed citations

20.

Stein, Evan A., Michael H. Davidson, Adrian S. Dobs, et al.. (1998). Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients. The American Journal of Cardiology. 82(3). 311–316. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact